TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06368063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huaier granule
Description: Huaier Granules: Oral administration, 10g once, 3 times a day, starting from 15-30 days after surgery until the end of the study, intolerable toxicity, withdrawal from the study for any reason, or death, whichever occurs first; Or the researcher determines that the subjects no longer benefit.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy drugs
Description: Accept treatment with Class 1A chemotherapy drugs recommended by CSCO (choose any one to receive treatment)~· Gemcitabine combine with capecitabine~Gemcitabine 1000mg/m\^2 intravenous infusion for more than 30 minutes, day 1, 8, 15,repeat every 4 weeks for a total of 6 cycles.~· mFOLFIRINOX solution~Oxaliplatin 85mg/m\^2 intravenous infusion for 2 hours, day 1 Ilitacan 150mg/m\^2 intravenous infusion for more than 30-90 minutes, day 1 Leucovorin calcium 400mg/m\^2 intravenous infusion for 2 hours, day 1 5-FU 2400mg/m\^2, continuous intravenous infusion for 46 hours, repeated every 2 weeks, administered until 24 weeks.~* Gemcitabine monotherapy~  1000mg/m\^2 intravenous infusion, day 1 qw x 7, rest for 1 week Afterwards, qw × 3, take a week off, and administer medication for 6 months.~* Tegio capsules monotherapy~Take tegio capsules orally, 80mg/d, day 1-28, repeated every 6 weeks, administered until 6 months.
Study: NCT05729620

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant of STARgraft-3 shunt in the upper arm and subsequent use for hemodialysis access
Description: After healing from the surgical procedure, the graft will be routinely cannulated for hemodialysis sessions. Periodic evaluations of blood flow by ultrasound imaging will be made over the study period. Established standards of care will be followed as needed to maintain dialysis function.
Study: NCT06702228

Intervention type: DIAGNOSTIC_TEST
Intervention: Computer-tomography of the thorax (CT Thorax)
Description: Radiological assessment via CT Thorax, preferably high-resolution CT thorax at baseline on entering the study and at one year. CT images will be collected on study end. CT images in all subjects will be evaluated by three readers blinded to any other interpretation and conforming to ATS-guidelines. Coded data from CT scans will be shared with our collaborator Professor Simon Walsh at Imperial College, London who will use computational methods to identify novel radiologic phenotypes linked to disease behaviour of our patient's fibrotic lung disease.
Study: NCT05195320

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reinvention with MS
Description: A manualized group therapy to build self-efficacy among people living with multiple sclerosis.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Reinvention with MS
Description: A manualized group therapy to build self-efficacy among people living with multiple sclerosis.
Study: NCT06702228

Intervention type: DIAGNOSTIC_TEST
Intervention: Computer-tomography of the thorax (CT Thorax)
Description: Radiological assessment via CT Thorax, preferably high-resolution CT thorax at baseline on entering the study and at one year. CT images will be collected on study end. CT images in all subjects will be evaluated by three readers blinded to any other interpretation and conforming to ATS-guidelines. Coded data from CT scans will be shared with our collaborator Professor Simon Walsh at Imperial College, London who will use computational methods to identify novel radiologic phenotypes linked to disease behaviour of our patient's fibrotic lung disease.

Intervention type: OTHER
Intervention: Quality of life questionnaires.
Description: Qality of life questionnaires including; modified Medical Research Council (mMRC) dyspnea scale, The King's Brief Interstitial Lung Disease Questionnaire (KBILD), The Leister Cough Questionnaire and the EQ-5D-3L questionnaire are measured at 0, 6 and 12 months

Intervention type: OTHER
Intervention: Quality of life questionnaires.
Description: Qality of life questionnaires including; modified Medical Research Council (mMRC) dyspnea scale, The King's Brief Interstitial Lung Disease Questionnaire (KBILD), The Leister Cough Questionnaire and the EQ-5D-3L questionnaire are measured at 0, 6 and 12 months

Intervention type: OTHER
Intervention: Quality of life questionnaires.
Description: Qality of life questionnaires including; modified Medical Research Council (mMRC) dyspnea scale, The King's Brief Interstitial Lung Disease Questionnaire (KBILD), The Leister Cough Questionnaire and the EQ-5D-3L questionnaire are measured at 0, 6 and 12 months

Intervention type: DIAGNOSTIC_TEST
Intervention: Genetic Testing
Description: 10ml of serum will be collected for DNA extraction and analysed for causative and at risk genetic mutations

Intervention type: DIAGNOSTIC_TEST
Intervention: Genetic Testing
Description: 10ml of serum will be collected for DNA extraction and analysed for causative and at risk genetic mutations

Intervention type: DIAGNOSTIC_TEST
Intervention: Genetic Testing
Description: 10ml of serum will be collected for DNA extraction and analysed for causative and at risk genetic mutations

Intervention type: DIAGNOSTIC_TEST
Intervention: Spirometry
Description: We will carry out spirometry at baseline, 6 and 2 months including forced vital capacity and diffusing capacity of the lungs for carbon monoxide.
Study: NCT05074550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPMX-T003
Description: As an observation and evaluation method, for each dose, in principle, inpatient observation is performed for 1 week from the day before administration, and then safety and pharmacodynamic tests are evaluated by visiting the hospital every 2 weeks.
Study: NCT06702488

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine
Description: 20 mg/kg as a loading dose over 10 minutes before induction then a maintenance dose of 5 mg/kg/hour, which will also be discontinued at the skin closure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine
Description: 20 mg/kg as a loading dose over 10 minutes before induction then a maintenance dose of 5 mg/kg/hour, which will also be discontinued at the skin closure.
Study: NCT05366725

Intervention type: DRUG
Intervention: Avelumab
Description: As provided in real world practice
Study: NCT05850260

Intervention type: DEVICE
Intervention: Macintosh laryngoscope
Description: During the pre-implementation period (6 months), the 35 assigned attending anesthetists will perform all tracheal intubations in the operation room according to the standard of care using the standard Macintosh direct laryngoscope as a first intubation option

Intervention type: DEVICE
Intervention: Videolaryngoscope
Description: During the post-implementation period (6 months), the 35 assigned attending anesthetists will perform all tracheal intubations using their personal McGrath Mac videolaryngoscope as a first intubation option.
Study: NCT06303687

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR-PAT
Description: Virtual Reality Pain Alleviation Therapy (VR-PAT) played on a Pico Neo 3 Pro Eye device
Study: NCT06411782

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foam roller
Description: In foam roller application, a partitioned FR from the Trigger Point Grid 2.0 brand, measuring 33x14 cm and weighing 0.9 kg, with an inner part made of polyvinylchloride (PVC), will be used. Participants will roll the segmented FR with slight flexion-extension by placing the FR on the SCM muscle to apply FR from the starting point to the end point of that muscle region for the selected SCM muscle, with the person in the side stance position against the wall. This action will consist of 3 sets of 1 minute each, with a 30-second rest period between each set. It will be applied once for each region, including the right and left SCM muscle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Inspiratory muscle training will be done with a resistive exercise device at 80% of MIP max and for 30 breaths.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Inspiratory muscle training will be done with a resistive exercise device at 80% of MIP max and for 30 breaths.
Study: NCT04883892

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BMAC
Description: patients will be injected with BMAC into the ankle joint, after treatment patients will be followed up to 24 months. In particular patients will be assessed after treatment at 1, 3, 6, 12 and 24 months.~During the injection, samples of BMAC will be collected for the characterization of the phenotype markers and clonogenic capability

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HA
Description: patients will be treated with two injection of HA, one every 15 days, into the ankle joint. After treatment these patients will be followed up to 24 months. At 12 months patients can decide to cross.over in the BMAC arm treatment. After cross-over patients will be assessed for further 12 months.
Study: NCT05022823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression sleeve, worn during exercise
Description: Participants wear their daytime compression sleeve during the DPRE program.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjustable Compression (AC) garment, worn during exercise
Description: Participants wear an Adjustable Compression (AC) garment during the DPRE program. Participants will be fitted for an Adjustable Compression garment and instructed in its application by a physical therapist.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression sleeve, daytime wear
Description: Compression sleeve worn for at least 12 hours per day, seven days a week.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression sleeve, daytime wear
Description: Compression sleeve worn for at least 12 hours per day, seven days a week.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compression sleeve, daytime wear
Description: Compression sleeve worn for at least 12 hours per day, seven days a week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decongestive Progressive Resistance Exercise program
Description: Supervised DPRE exercise program, twice a week for 12 weeks. Exercises will be individualized and offered in a group-based format.~After the 12-week intervention, participants will continue the same program (independently) twice weekly for an additional 12 weeks at home or in a community-based fitness center or attend supervised group exercise sessions virtually.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decongestive Progressive Resistance Exercise program
Description: Supervised DPRE exercise program, twice a week for 12 weeks. Exercises will be individualized and offered in a group-based format.~After the 12-week intervention, participants will continue the same program (independently) twice weekly for an additional 12 weeks at home or in a community-based fitness center or attend supervised group exercise sessions virtually.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise program
Description: Participants are provided with a home exercise program that follows the decongestive exercise sequence and instructed to perform the exercise sequence once daily for a 10-15 minute period.
Study: NCT05035706

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and tissue sample collection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Medical records reviewed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photography
Description: Photographs taken
Study: NCT05338671

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthetic
Description: Patients will receive inferior alveolar nerve block injection following endodontic treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthetic
Description: Patients will receive inferior alveolar nerve block injection following endodontic treatment.
Study: NCT05523531

Intervention type: OTHER
Intervention: Self-administered questionnaires
Description: * Neuropathic Eye Pain Questionnaire~* 5-item Dry Eye Evaluation Questionnaire (DEQ-5)~* Visual Impact Assessment Questionnaire~* Concise Ophthalmic Pain Questionnaire~* Questionnaire to evaluate the effectiveness and tolerance of treatments~* Chronic pain questionnaire

Intervention type: PROCEDURE
Intervention: Bilateral ophthalmologic examination
Description: * Examination of the ocular surface and eyelids Slit lamp with fluorescein instillation: Oxford scheme and Break-up time, Schirmer's test, Oxybuprocaine test~* Lipiview® test~* Examination of corneal sensitivity with the Cochet-Bonnet esthesiometer~* In vivo morphological examination of the subepithelial nerve plexus of the cornea by confocal microscopy
Study: NCT06634407

Intervention type: PROCEDURE
Group type: OTHER
Intervention: transcatheter closure
Description: using transcatheter closure of PDA to detect outcome of patients with PDA
Study: NCT04692103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 16 Alpha-Fluoroestradiol
Description: Undergo F-18 FES PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo F-18 FES PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo F-18 FES PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo FDG PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT05846503

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 1. Quality and info management system
Description: 1. The intervention package prioritizes information and quality management with a focus on HTN screening, diagnosis, and treatment. From the point-of-care, flow charts placed in the patient file will ensure that vitals are performed in accordance with national guidelines.~2. The care coordinator will present data to clinic staff in multi-disciplinary meetings, providing an opportunity for programmatic feedback and discussion.~3. Patients will be encouraged to complete the vital signs measurements at each clinic visit. They will be provided with their BP readings and given info about what their reading means. They will be issued with pocket sized color coded booklets providing info on the measurement and what to do to control their BP.~4. Task shifting: A care coordinator will be the champion of the intervention package for the clinic.~5. All staff will receive apt training on how to use the patient flow chart, info management system and how to respond to abnormal BP values.
Study: NCT05571618

Intervention type: DRUG
Intervention: ADC
Description: Patients with prior exposure to ADC (either in the adjuvant setting or metastatic disease are allowed).
Study: NCT04748510

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Functionally Aligned Total Knee Arthroplasty
Description: Femoral + tibial osteotomy planned for equal resection of femoral condyles to replicate patient anatomy. In coronal plane, distal femoral resection of 6.5mm subchondral bone from medial + lateral condyles, adjusted 1-3mm for compensation of wear. Proximal tibia, 7mm resection from subchondral bone from medial + lateral tibial plateau. Sagittal plane, resection angle determined intraoperatively to closely match native femoral flexion + tibial slope. Axial plane: posterior femoral resection 6.5mm from the subchondral bone of medial and lateral posterior condyles. Tibial rotation aligned to Akagi's line. Adjustments will be made to bony alignment to balance soft tissues within boundaries of 6° varus/3° valgus HKA alignment. Femoral component alignment limited to 6° valgus/3° varus in coronal plane. Tibial alignment limited 6° varus/3° valgus in coronal plane. Combined flexion of components limited to 10° flexion. Soft tissue release if balance within boundaries not achieved.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanically Aligned Total Knee Arthroplasty
Description: Tibial and femoral osteotomies in the coronal plane will be planned perpendicular to the tibial and femoral mechanical axes respectively to achieve neutral overall alignment. Soft tissue balance will be assessed and minor adjustments to bony alignment made to balance the knees with a maximal adjustment of two degrees valgus and two degrees varus of coronal alignment from neutral. Femoral rotation will be planned to surgical epicondylar axis and adjustments to rotation made to allow equal flexion and extension balance (to within 1mm). If balance can not be achieved within these boundaries then soft tissue release will be undertaken. In the sagittal plane, 0-3° degrees of posterior tibial slope and 0-5° of femoral component flexion will be used to optimise implant sizing whilst preventing notching. In the axial plane, the tibial component aligned to Akagi's line, which connects the medial border of the patellar tendon attachment to the middle of the posterior cruciate ligament.
Study: NCT05508061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro Cartridge [Lyumjev]
Description: Administration of Lyumjev in combination with the AP system

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro Cartridge
Description: Administration of Humalog in combination with the AP system (standard therapy)
Study: NCT05196412

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PulseOn Arrhythmia Monitor device
Description: Wearing of the wrist device for a period of two weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PulseOn Arrhythmia Monitor device
Description: Wearing of the wrist device for a period of two weeks
Study: NCT05459636

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-resistance inspiratory muscle strength training
Description: Participants will perform high-resistance inspiratory muscle strength training on a daily basis for eight weeks using a handheld device that produces resistance that increases the effort of breathing in.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Very-low-resistance inspiratory muscle strength training
Description: Participants will perform very-low-resistance inspiratory muscle strength training on a daily basis for eight weeks using a handheld device that produces resistance that increases the effort of breathing in.
Study: NCT06572410

Intervention type: DEVICE
Intervention: EnVisio Navigation System
Description: Patient will be undergoing BCS Breast Conserving Surgery treatment for DCIS or invasive breast cancer with EnVisio Navigation System.
Study: NCT06414499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTNK-tPA
Description: 0.25mg/kg, the maximum dose does not exceed 25mg: 1 vial is dissolved in 3ml of sterile water for injection to prepare a medicinal solution with a concentration of 5.33mg/ml. Calculate the total amount of the drug according to the weight of participant, and the maximum dose shall not exceed 25 mg. It is administered as a single bolus intravenous injection, and the injection is completed within 5-10 seconds.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Standard medical care according to the guideline (Stroke. 2019;50(12): e344-e418.). Antiplatelet therapy is chosen by researchers-Single/dual antiplatelet therapy can be chosen.
Study: NCT06573502

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Prp with prf or prp or prf
Description: Combination

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Prp with prf or prp or prf
Description: Combination

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Prp with prf or prp or prf
Description: Combination
Study: NCT04844229

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral transnasal sphenopalatine ganglion block.
Description: SPG block will be performed with the patient in supine position using cotton-tipped plastic hollow applicator inserted in the nose with the swab soaked in 1.5 ml 10%lignocaine. The applicator will be inserted parallel to the floor of the nose until resistance encountered. The swab will be rested in the pterygopalatine fossa superior to the middle turbinate and removed after 10 min. This procedure will be repeated in the other nostril too.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral ultrasound guided greater occipital nerve block.
Description: GONB will be performed with the patients lying in prone position using high frequency (6-13 MHz) probe of Siemens Acuson X300 machine placed in transverse orientation lateral to external occipital protuberance parallel to the superior nuchal line to detect occipital artery where the nerve is located medial to it 1.5inch; then 20 gauge needle will be inserted out of plane to avoid vascular injury. 4 ml of treatment solution containing 2.5 mg/ml bupivacaine and 1 mg/ml dexamethasone (prepared by adding 2 ml bupivacaine 0.5% + 1 ml dexamethasone + 1 ml saline) will be injected on each side.
Study: NCT05800288

Intervention type: DRUG
Intervention: Propofol
Description: Patients will be observationally included in the Elveld TCI or Schnider TCI group. The TCI model is choosen at anesthesiologist's discreption, as suggested in literature

Intervention type: DRUG
Intervention: Propofol
Description: Patients will be observationally included in the Elveld TCI or Schnider TCI group. The TCI model is choosen at anesthesiologist's discreption, as suggested in literature
Study: NCT04631055

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: drug coated balloon
Description: paclitaxel coated balloon catheter for intracranial PTA treatment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stent system
Description: The Intracranial Stent System comprises of a balloon expandable stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.The product, APOLLO™ stent system, has the indication of endovascular treatment for intracranial stenosis approved by NMPA.
Study: NCT06115707

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The lying flat (0°-10°) head position for 72 hours
Description: The lying flat (0°-10°) head position for 72 hours after endovascular therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The The head elevation (30°-40°) position for 72 hours
Description: The head elevoatin (30°-40°) position for 72 hours after endovascular therapy.
Study: NCT06234969

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Theta Burst Stimulation to the Intraparietal Sulcus
Description: Continuous Theta Burst Stimulation delivered to the Intraparietal Sulcus

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Continuous Theta Burst Stimulation
Description: Sham Continuous Theta Burst Stimulation